Rani Therapeutics Holdings (RANI) Net Cash Flow (2020 - 2026)

Rani Therapeutics Holdings has reported Net Cash Flow for 7 years, with the latest figure at -$4.8 million in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 4645.71% year-over-year to -$4.8 million in Q2 2026; TTM through Jun 2026 was -$5.6 million, a 199.05% decrease from a year earlier, with the FY2025 full-year figure at $14.6 million, up 792.48% from the prior year.
• Net Cash Flow was -$4.8 million for Q2 2026 at Rani Therapeutics Holdings, up from -$9.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $14.2 million in Q4 2025, with the low at -$69.5 million in Q3 2022.
• Average Net Cash Flow over 5 years is -$6.2 million, with a median of -$2.5 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Net Cash Flow jumped 2852.23% in 2025, then plunged 4645.71% in 2026.
• Over 5 years, Net Cash Flow stood at -$212000.0 in 2022, then jumped by 520.75% to $892000.0 in 2023, then plunged by 157.74% to -$515000.0 in 2024, then surged by 2852.23% to $14.2 million in 2025, then sank by 133.67% to -$4.8 million in 2026.
• The last three Net Cash Flow figures came in at -$4.8 million (Q2 2026), -$9.0 million (Q1 2026), and $14.2 million (Q4 2025), per Business Quant data.